Shanghai Reach Medical Instruments Co., Ltd. (“Shanghai Reach”) was jointly founded by investors from the healthcare sector, industry experts, and seasoned professionals in marketing and operations. Reach focuses on third-party logistics and services for clinical diagnostics, distribution of clinical testing equipment and reagent consumables, as well as co-building large-scale laboratory facilities.

Business?Area

1. Third-Party Logistics and Services for Clinical Diagnostics

This includes integrated logistics for IVD reagents and consumables, laboratory information systems, and research collaborations. Professional logistics providers—independent of hospitals and manufacturers—offer outsourced delivery and management services, ensuring the long-term, stable supply of all lab consumables. This efficient model streamlines hospital procurement, enhances product quality and IT services through centralized purchasing and standardized processes, and lowers operational costs. Utilizing modern ERP systems, hospitals benefit from real-time ordering, tracking, receiving, and reporting. On-site warehousing enables zero-inventory operations, minimizing waste and stockouts. Fully compliant with medical device regulations, all certifications and licenses are properly filed. With 70% of U.S. hospitals already adopting this model, hundreds in China have followed suit. Proven results include a 60% reduction in operating costs, 60% increase in service efficiency, 56% boost in business focus, and 40% reduction in staff, allowing hospitals to concentrate more resources on their core specialties.

2. Distribution of Clinical Testing Equipment and Reagents

Reach distributes a wide range of clinical instruments and consumables, including large automated biochemical analyzers, chemiluminescence testing systems, three- and five-part hematology analyzers, along with their respective components, reagents, and consumables.

3. Co-Building of Central Laboratories in Regional and Higher-Level Hospitals

Services include automated lab assembly lines at international standards, advanced laboratory management systems for mobile and self-service data access, and end-to-end sample collection solutions for community and smaller hospitals. Reach also provides regional diagnostic data management systems enabling local result recognition, expert technical support for project and research development, and opportunities for training and exchange at leading hospitals and laboratories. Support for achieving ISO or CAP certification is also available.

Professional Team

All team members hold university degrees or higher, with backgrounds in medicine, biology, or marketing management. The core management team has extensive experience in marketing and managing clinical testing products, successful distribution of renowned international diagnostic brands, and a strong track record of long-term collaborations with hospitals across various projects.

Marketing Concept

Mutual growth for shared success.

Vision

To become a leading service provider in the industry.

Quality Commitment

We are committed to providing reputable domestic and international products through a standardized, rigorous, and ethical operational system, ensuring fair, efficient, and high-quality solutions and continuous improvement for every partner.

Service Assurance

24/7 uninterrupted support, ready to meet client needs at any time.

Tianjin Rebio Biotech Co., Ltd. (“Rebio”) is a high-tech enterprise and a majority-owned subsidiary of Shanghai Reigncom Biotech, specializing in the R&D, production, and commercialization of third-party quality control (QC) products.

Rebio is committed to delivering high-quality QC products characterized by wide applicability, strong flexibility, and exceptional stability. It also provides professional consulting services for ISO 15189 quality management systems, aiming to enhance overall diagnostic service quality by building an integrated medical laboratory quality service ecosystem.

In close collaboration with renowned experts and specialized laboratories at home and abroad, Rebio operates internationally compliant R&D and production platforms, as well as standardized, large-scale manufacturing facilities and a comprehensive marketing network—delivering superior products and service experiences to clients.

Upholding the corporate mission “Science Elevates Lives,” Rebio adheres to the principles of “quality first, integrity-driven operations, and continuous innovation” to contribute to the ongoing advancement of laboratory quality control.

With a well-established nationwide commercial network, Rebio is positioned to consistently deliver high-quality products and outstanding services—and welcomes collaboration with partners who share the vision of mutual success.

Reidge Inc. (USA), wholly owned by Shanghai Ridge Technology, is an innovative enterprise based in California, USA. It focuses on the development, sales, and service of precision diagnostic products, with clinical mass spectrometry as its core technology platform. Reidge is dedicated to developing high-sensitivity, high-accuracy in vitro diagnostic (IVD) solutions to advance the field of personalized medicine.

Reidge addresses critical clinical diagnostic challenges, with product pipelines spanning high-impact disease areas such as neurodegenerative disorders, infectious diseases, and cancer. It has formed strategic collaborations with leading U.S. academic and medical institutions, including Stanford University Hospital and the University of Michigan Medical School.

In addition to serving the North American market, Reidge is actively expanding into Asia, Australia, and Europe. Looking ahead, it will continue to deepen its presence in the diagnostic landscape and join forces with global partners to usher in a new era of precision, efficiency, and personalization in healthcare.